In the realm of cancer treatment, intraoperative radiation therapy (IORT) presents a viable option for consideration.
At the forefront of this innovative approach, concentrated doses of radiation are administered directly to the tumor site during surgery, effectively shielding surrounding healthy tissues from damage.
Research and data collected at PromiseCare Medical Group in Hemet, California, indicate that IORT is particularly effective in treating early-stage breast cancer.
Patients who undergo IORT experience comparable survival rates to those achieved through traditional methods while also benefiting from an improved quality of life and reduced overall treatment time.
The effectiveness of IORT lies in its ability to streamline recovery, target remaining cancer cells, and enhance treatment outcomes.
By understanding the intricacies of this treatment option, patients can make informed decisions about their care.
Overview
Intraoperative radiation therapy (IORT) is a treatment that delivers a concentrated dose of radiation directly to the tumor site during surgery, shielding surrounding healthy tissues from its effects. This approach allows for immediate treatment of residual cancer after tumor removal, enhancing overall efficacy and reducing the risk of local recurrence.
IORT directly delivers a high radiation dose to the tumor site, minimizing exposure to surrounding healthy tissues. This treatment option is effective for early-stage breast cancer, providing comparable survival rates to traditional radiation methods but with fewer complications and a reduced overall treatment time.
Studies have shown that IORT offers benefits such as improved quality of life and patient convenience.
IORT precisely targets radiation treatment, reducing the risk of harm to surrounding tissues; this cutting-edge treatment is revolutionizing the way cancer is fought, and it’s an option worth exploring with a healthcare team.
Types
Intraoperative radiation therapy (IORT) takes various forms in treating cancer. When considering IORT for breast cancer or other types of cancer, understanding the different ways it can be administered is essential to ensure safety and effectiveness.
One common type of IORT is intraoperative electron radiation therapy, which delivers high doses of targeted radiation directly to the tumor site during surgery. Advanced equipment makes this approach possible. This type of IORT is indicated for various cancers, including sarcomas and neuroblastoma, and can also be used specifically for breast cancer treatment during lumpectomy.
Unlike traditional radiation therapy that requires multiple sessions over several weeks, IORT typically involves a single high dose of radiation. This treatment can be used alone or in combination with external beam radiation therapy to enhance overall effectiveness and patient outcomes. IORT provides a targeted and efficient treatment that minimizes exposure to radiation.
Why it’s done
Intraoperative radiation therapy (IORT) is a treatment option that can be used during cancer surgery. It involves delivering a concentrated dose of radiation directly to the tumor site to target any remaining cancer cells and minimize damage to surrounding healthy tissue. By doing so, IORT reduces the risk of local recurrence, a significant concern for cancer patients.
IORT is used to address the potential for micro-metastases that may remain in the tumor bed after surgical excision. This immediate treatment during surgery can streamline the recovery process by combining surgical and radiation therapies into a single session.
IORT may enhance treatment effectiveness and improve quality of life by reducing the need for additional treatment sessions. Studies show that IORT can offer comparable survival rates to traditional radiation therapy with fewer treatment sessions required.
Who it’s for
Patients facing a cancer diagnosis find themselves maneuvering a complex web of treatment options. As they navigate this challenging landscape, they may wonder if Intraoperative Radiation Therapy (IORT) suits them.
IORT is primarily indicated for patients aged 50 or older with early-stage breast cancer, particularly those with grade 1 or 2, node-negative, HER2 negative, and ER+ invasive ductal carcinoma (IDC).
A thorough review of the patient’s clinical profile is conducted. Factors that may exclude someone from IORT include prior radiation treatments, a history of ipsilateral breast cancer, or specific unfavorable cancer characteristics.
Adherence to endocrine therapy is also considered, as it dramatically influences local recurrence rates. If the eligibility criteria are met, IORT may offer a targeted and effective treatment option for breast cancer. Patients can work with their medical team to decide whether IORT is right.
Studies have shown that many patients may be suitable for IORT, while others may be considered cautionary or unsuitable.
The decision to undergo IORT should be made on a case-by-case basis, considering individual factors and medical history.
Risks
The possibility of IORT brings a new set of considerations, shifting the focus from treatment suitability to potential risks and challenges. The risks associated with IORT are multifaceted, affecting the body, mind, and spirit.
Localized side effects, such as skin irritation, swelling, or changes in breast shape, can vary depending on individual factors. Less common but serious side effects may include damage to surrounding healthy tissues, leading to potential long-term complications like fibrosis or changes in organ function.
Some studies have noted a higher risk of ipsilateral breast tumor recurrence, raising concerns about IORT’s long-term effectiveness. Additionally, refusing or not adhering to endocrine therapy after IORT may result in a higher recurrence rate.
Understanding these risks can help inform decision-making and navigate the IORT journey with a clearer sense of what to expect. Acknowledging potential challenges can better prepare individuals for the road ahead.
How you prepare
Before commencing Intraoperative Radiation Therapy, a thorough evaluation is conducted to confirm eligibility. This assessment determines whether IORT is the proper treatment, taking into account tumor characteristics and overall health.
Discussing medical history, including previous treatments or surgeries, is essential, as these may impact candidacy for IORT.
To guarantee safety, certain medications, such as blood thinners or non-steroidal anti-inflammatory drugs (NSAIDs), must be avoided for a specified period before the procedure. This precaution minimizes the risk of bleeding during treatment.
Pre-procedure imaging tests, like mammograms or MRIs, may also be conducted to assess the size and location of the tumor accurately.
A multidisciplinary team collaborates to establish a tailored treatment plan that addresses specific needs. This team effort ensures that the most effective treatment possible is received.
What you can expect
When undergoing intraoperative radiation therapy (IORT), a single dose of radiation is delivered directly to the tumor site immediately after surgical removal of the tumor. This treatment is performed under general anesthesia, ensuring comfort and eliminating pain.
An applicator is inserted into the tumor cavity, precisely delivering the prescribed radiation dose. This approach minimizes exposure to surrounding tissue, reducing the risk of damage to healthy cells.
IORT typically requires fewer treatment sessions compared to traditional radiation therapy, which often spans several weeks. This condensed treatment schedule can be more convenient for patients.
Following treatment, the care team will closely monitor progress, evaluating the effectiveness of the treatment and managing potential side effects, which are often lower than those associated with standard radiation therapy.
Results
Facing cancer can be an intimidating journey, and understanding the outcomes of treatments like intraoperative radiation therapy (IORT) is crucial in making informed care decisions. When considering IORT, it’s essential to know the results of this treatment.
Studies have shown that in a group of patients who underwent IORT, the ipsilateral breast tumor recurrence (IBTR) rate was 3.7% at 3.5 years. This rate is slightly higher than reported rates in other studies, emphasizing the need for careful patient selection.
The complication rate for IORT is around 14.7%, with seroma being the most common complication, occurring in approximately 8.2% of patients. Adherence to endocrine therapy significantly impacts outcomes, with higher recurrence rates observed in patients who refuse or don’t complete therapy compared to those who adhere.
The local recurrence rate for patients treated with IORT has been reported to be around 2.0%, with a median time to local recurrence of 29 months. These results highlight the importance of following a treatment plan and discussing any concerns with a healthcare team to guarantee the best possible outcome.